Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AP-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : PACE
Deal Size : $1.2 million
Deal Type : Funding
ArrePath Secures £1M PACE Grant to Advance Antibiotics for Drug-Resistant Infections
Details : The proceeds will be used to develop a new class of antibiotics designed to address multidrug-resistant (MDR) infections, including AP-001 for the treatment of complicated urinary tract infections.
Brand Name : AP-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 19, 2024
Lead Product(s) : AP-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : PACE
Deal Size : $1.2 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?